HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more
Market Cap & Net Worth: HeraMED Limited (1I4)
HeraMED Limited (F:1I4) has a market capitalization of $26.86 Million (€26.17 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #26191 globally and #2866 in its home market, demonstrating a -4.08% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HeraMED Limited's stock price €0.02 by its total outstanding shares 1113653427 (1.11 Billion).
HeraMED Limited Market Cap History: 2026 to 2026
HeraMED Limited's market capitalization history from 2026 to 2026. Data shows growth from $26.86 Million to $26.86 Million (0.00% CAGR).
HeraMED Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HeraMED Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 1I4 by Market Capitalization
Companies near HeraMED Limited in the global market cap rankings as of March 19, 2026.
Key companies related to HeraMED Limited by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
HeraMED Limited Historical Marketcap From 2026 to 2026
Between 2026 and today, HeraMED Limited's market cap moved from $26.86 Million to $ 26.86 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €26.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of HeraMED Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.86 Million USD |
| MoneyControl | $26.86 Million USD |
| MarketWatch | $26.86 Million USD |
| marketcap.company | $26.86 Million USD |
| Reuters | $26.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.